About Bellicum Pharmaceuticals (NASDAQ:BLCM)
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also comprise BPX-701, a T cell receptors (TCR) based therapy in Phase I clinical trial for the treatment of malignant cells expressing the preferentially-expressed antigen in melanoma; and CD19, a chimeric antigen receptor T cell therapy for expressing B cell malignancies setting. It has collaboration agreements with Adaptimmune Therapeutics plc to evaluate, develop, and commercialize T cell therapies; and Academisch Ziekenhuis Leiden for research to discover and validate high-affinity TCR product candidates targeting various cancer-associated antigens. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BLCM
CUSIPN/A
Phone832-384-1100
Debt
Debt-to-Equity Ratio0.41%
Current Ratio8.37%
Quick Ratio8.37%
Price-To-Earnings
Trailing P/E Ratio-2.65
Forward P/E Ratio-2.82
P/E GrowthN/A
Sales & Book Value
Annual Sales$190,000.00
Price / Sales1,328.67
Cash FlowN/A
Price / CashN/A
Book Value$2.55 per share
Price / Book2.95
Profitability
EPS (Most Recent Fiscal Year)($2.84)
Net Income$-91,770,000.00
Net MarginsN/A
Return on Equity-79.36%
Return on Assets-56.27%
Miscellaneous
Employees137
Outstanding Shares33,570,000
Bellicum Pharmaceuticals (NASDAQ:BLCM) Frequently Asked Questions
What is Bellicum Pharmaceuticals' stock symbol?
Bellicum Pharmaceuticals trades on the NASDAQ under the ticker symbol "BLCM."
How were Bellicum Pharmaceuticals' earnings last quarter?
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) announced its quarterly earnings results on Tuesday, March, 13th. The biopharmaceutical company reported ($0.61) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.08. The biopharmaceutical company had revenue of ($0.07) million for the quarter, compared to analyst estimates of $0.08 million. View Bellicum Pharmaceuticals' Earnings History.
What price target have analysts set for BLCM?
7 equities research analysts have issued 1 year price targets for Bellicum Pharmaceuticals' shares. Their forecasts range from $6.85 to $31.00. On average, they expect Bellicum Pharmaceuticals' stock price to reach $19.2643 in the next twelve months. View Analyst Ratings for Bellicum Pharmaceuticals.
What are Wall Street analysts saying about Bellicum Pharmaceuticals stock?
Here are some recent quotes from research analysts about Bellicum Pharmaceuticals stock:
- 1. Cantor Fitzgerald analysts commented, "Complex Cases. The three cases of encephalopathy occurred in three patients, certain of whom had failed prior transplantation, have a history of immunodeficiency, infection, and/or treatment with rimiducid and other medications. To-date, Bellicum has treated over 240 patients with allogeneic haploidentical transplants with limited rates of transplant-related mortality. This compares to historical studies of allogeneic transplantation by the Center for International Blood & Marrow Transplant Research that have demonstrated that more than a third of deaths occur from occurrences of GvHD and infection, which BPX-501 is aimed at addressing. That being said, we are not yet clear on the relationship of these encephalopathy events to BPX-501 treatment, which lowers our overall confidence in the BPX-501 program." (1/31/2018)
- 2. According to Zacks Investment Research, "Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. The Company's lead clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials. It is also developing BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Bellicum Pharmaceuticals, Inc. is based in Houston, Texas. " (1/22/2018)
Who are some of Bellicum Pharmaceuticals' key competitors?
Some companies that are related to Bellicum Pharmaceuticals include Achillion Pharmaceuticals (ACHN), ObsEva (OBSV), Zealand Pharma (ZEAL), MediciNova (MNOV), Innate Pharma (IPHYF), ProMetic Life Sciences (PFSCF), Isotechnika Pharma (AUPH), Sinovac Biotech (SVA), Concert Pharmaceuticals (CNCE), Synergy Pharmaceuticals (SGYP), Depomed (DEPO), Syros Pharmaceuticals (SYRS), Cara Therapeutics (CARA), Albireo Pharma (ALBO), Kala Pharmaceuticals (KALA), Corbus Pharmaceuticals (CRBP), Mersana Therapeutics (MRSN) and Cytokinetics (CYTK).
Who are Bellicum Pharmaceuticals' key executives?
Bellicum Pharmaceuticals' management team includes the folowing people:
- Mr. Alan A. Musso, CFO & Treasurer (Age 56)
- Mr. Thomas J. Farrell, Consultant (Age 55)
- Dr. Annemarie Moseley M.D., Ph.D., Consultant (Age 63)
- Mr. Richard A. Fair, Pres, CEO & Director (Age 49)
- Dr. David M. Spencer, Chief Technology Officer (Age 56)
When did Bellicum Pharmaceuticals IPO?
(BLCM) raised $101 million in an initial public offering (IPO) on Thursday, December 18th 2014. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray served as the underwriters for the IPO and Trout Capital was co-manager.
Has Bellicum Pharmaceuticals been receiving favorable news coverage?
News coverage about BLCM stock has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Bellicum Pharmaceuticals earned a news impact score of 0.14 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 46.87 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
How do I buy shares of Bellicum Pharmaceuticals?
Shares of BLCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Bellicum Pharmaceuticals' stock price today?
One share of BLCM stock can currently be purchased for approximately $7.52.
How big of a company is Bellicum Pharmaceuticals?
Bellicum Pharmaceuticals has a market capitalization of $253.13 million and generates $190,000.00 in revenue each year. The biopharmaceutical company earns $-91,770,000.00 in net income (profit) each year or ($2.84) on an earnings per share basis. Bellicum Pharmaceuticals employs 137 workers across the globe.
How can I contact Bellicum Pharmaceuticals?
Bellicum Pharmaceuticals' mailing address is 2130 WEST HOLCOMBE BOULEVARD SUITE 800, HOUSTON TX, 77030. The biopharmaceutical company can be reached via phone at 832-384-1100 or via email at [email protected]
MarketBeat Community Rating for Bellicum Pharmaceuticals (BLCM)
MarketBeat's community ratings are surveys of what our community members think about Bellicum Pharmaceuticals and other stocks. Vote "Outperform" if you believe BLCM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLCM will underperform the S&P 500 over the long term. You may vote once every thirty days.
Bellicum Pharmaceuticals (NASDAQ:BLCM) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for Bellicum Pharmaceuticals in the last 12 months. Their average twelve-month price target is $19.2643, suggesting that the stock has a possible upside of 156.17%. The high price target for BLCM is $31.00 and the low price target for BLCM is $6.85. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.86 | 2.71 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $19.2643 | $18.00 | $26.20 | $26.20 |
| Price Target Upside: | 156.17% upside | 122.77% upside | 186.03% upside | 155.36% upside |
Bellicum Pharmaceuticals (NASDAQ:BLCM) Consensus Price Target History
Bellicum Pharmaceuticals (NASDAQ:BLCM) Analyst Ratings History
Show:
(Data available from 4/21/2016 forward)
Bellicum Pharmaceuticals (NASDAQ:BLCM) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Bellicum Pharmaceuticals (NASDAQ BLCM) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 18.77%
Institutional Ownership Percentage: 54.58%
Bellicum Pharmaceuticals (NASDAQ BLCM) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/19/2018 | Bros. Advisors Lp Baker | Major Shareholder | Sell | 880,735 | $8.20 | $7,222,027.00 | |  |
| 1/17/2018 | Bros. Advisors Lp Baker | Major Shareholder | Sell | 260,600 | $8.63 | $2,248,978.00 | | |
| 1/9/2018 | Alan K Smith | EVP | Sell | 487 | $9.40 | $4,577.80 | 2,087 | |
| 12/11/2017 | Alan A Musso | CFO | Sell | 17,117 | $9.33 | $159,701.61 | 31,585 | |
| 11/27/2017 | Alan A Musso | CFO | Sell | 6,206 | $9.89 | $61,377.34 | | |
| 7/24/2017 | Alan K. Smith | EVP | Sell | 437 | $11.85 | $5,178.45 | | |
| 7/13/2017 | Ken Moseley | VP | Sell | 13,823 | $12.26 | $169,469.98 | 14,314 | |
| 7/10/2017 | David M. Spencer | Insider | Sell | 10,000 | $11.54 | $115,400.00 | | |
| 5/25/2017 | Alan A. Musso | CFO | Sell | 6,311 | $12.24 | $77,246.64 | | |
| 3/24/2017 | Bros. Advisors Lp Baker | Major Shareholder | Buy | 166,666 | $12.00 | $1,999,992.00 | | |
| 2/7/2017 | Kevin M Slawin | Director | Sell | 30,000 | $12.54 | $376,200.00 | 84,206 | |
| 12/15/2016 | Kevin M Slawin | Insider | Sell | 30,000 | $15.45 | $463,500.00 | 84,206 | |
| 12/5/2016 | David M Spencer | Insider | Sell | 5,000 | $20.00 | $100,000.00 | 146,082 | |
| 12/1/2016 | Annemarie Moseley | COO | Sell | 25,000 | $17.54 | $438,500.00 | | |
| 11/28/2016 | Alan A. Musso | CFO | Sell | 29,300 | $19.51 | $571,643.00 | | |
| 9/23/2016 | Ken Moseley | VP | Sell | 11,800 | $20.10 | $237,180.00 | 444 | |
| 9/23/2016 | Kevin M Slawin | Insider | Sell | 23,416 | $20.12 | $471,129.92 | 95,464 | |
| 9/20/2016 | David M Spencer | Insider | Sell | 2,500 | $20.01 | $50,025.00 | 173,382 | |
| 9/20/2016 | Ken Moseley | VP | Sell | 2,200 | $20.01 | $44,022.00 | 1,044 | |
| 8/15/2016 | Ken Moseley | VP | Sell | 1,000 | $20.00 | $20,000.00 | | |
| 8/15/2016 | Kevin M Slawin | Insider | Sell | 67,000 | $19.31 | $1,293,770.00 | 100,079 | |
| 7/27/2016 | David M. Spencer | Insider | Sell | 10,000 | $15.00 | $150,000.00 | | |
| 7/18/2016 | Kevin M Slawin | CTO | Sell | 2,719 | $13.99 | $38,038.81 | 134,206 | |
| 7/15/2016 | Kevin M Slawin | CTO | Sell | 22,281 | $13.72 | $305,695.32 | 136,925 | |
| 6/2/2016 | Annemarie Moseley | COO | Sell | 25,000 | $13.00 | $325,000.00 | 18,486 | |
| 6/2/2016 | Ken Moseley | VP | Sell | 15,000 | $13.00 | $195,000.00 | 15,196 | |
| 4/22/2016 | Kevin M Slawin | CTO | Sell | 55,000 | $11.43 | $628,650.00 | 159,206 | |
| 1/4/2016 | Annemarie Moseley | COO | Sell | 35,000 | $19.07 | $667,450.00 | 251 | |
| 12/1/2015 | David M Spencer | Insider | Sell | 5,000 | $22.95 | $114,750.00 | 178,600 | |
| 11/24/2015 | Alan A Musso | CFO | Sell | 29,300 | $22.34 | $654,562.00 | 88,742 | |
| 11/2/2015 | Ken Moseley | VP | Sell | 15,000 | $13.00 | $195,000.00 | 97 | |
| 10/1/2015 | Thomas J Farrell | CEO | Sell | 2,500 | $14.58 | $36,450.00 | 63,862 | |
| 9/11/2015 | David M Spencer | Insider | Sell | 5,000 | $19.00 | $95,000.00 | 178,600 | |
| 9/1/2015 | Thomas J Farrell | CEO | Sell | 2,500 | $16.78 | $41,950.00 | 66,362 | |
| 7/15/2015 | Kevin M Slawin | CTO | Sell | 6,000 | $20.00 | $120,000.00 | | |
| 6/16/2015 | David M Spencer | Insider | Sell | 20,000 | $22.96 | $459,200.00 | | |
(Data available from 1/1/2013 forward)
Bellicum Pharmaceuticals (NASDAQ BLCM) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Bellicum Pharmaceuticals (BLCM) PT Set at $31.00 by Ladenburg Thalmann
www.americanbankingnews.com - April 20 at 5:52 PM |
 | Bellicum Pharmaceuticals Announces Closing of Public Offering
finance.yahoo.com - April 20 at 5:26 PM |
| Bellicum Pharmaceuticals' (BLCM) Outperform Rating Reiterated at Wells Fargo
www.americanbankingnews.com - April 20 at 4:16 PM |
| Bellicum Pharmaceuticals Target of Unusually High Options Trading (BLCM)
www.americanbankingnews.com - April 19 at 8:32 AM |
 | BRIEF-Bellicum Pharmaceuticals Announces Proposed Public Offering Of Common Stock
www.reuters.com - April 18 at 5:49 PM |
 | Why Now Is the Best Time for Bellicum to Raise Cash
www.msn.com - April 17 at 6:02 PM |
| Here's Why Bellicum Pharmaceuticals Dropped as Much as 14.6% Today
www.msn.com - April 17 at 6:02 PM |
| Here's Why Bellicum Pharmaceuticals Dropped as Much as 14.6% Today
finance.yahoo.com - April 17 at 6:02 PM |
| Bellicum Pharmaceuticals (BLCM) Upgraded at BidaskClub
www.americanbankingnews.com - April 17 at 10:29 AM |
| Brokers Issue Forecasts for Bellicum Pharmaceuticals, Inc.'s FY2018 Earnings (BLCM)
www.americanbankingnews.com - April 16 at 2:31 AM |
| Bellicum Pharmaceuticals (BLCM) Lowered to "Strong Sell" at BidaskClub
www.americanbankingnews.com - April 14 at 8:31 AM |
| Zacks: Brokerages Anticipate Bellicum Pharmaceuticals, Inc. (BLCM) Will Post Quarterly Sales of $80,000.00
www.americanbankingnews.com - April 14 at 1:45 AM |
 | Your Daily Pharma Scoop: Reata Provides Update, Assembly Biosciences Data, Bellicum's BPX-501
seekingalpha.com - April 13 at 8:14 AM |
| -$0.71 Earnings Per Share Expected for Bellicum Pharmaceuticals, Inc. (BLCM) This Quarter
www.americanbankingnews.com - April 12 at 11:14 PM |
| Bellicum Rallies After FDA Lifts Clinical Hold
www.msn.com - April 12 at 5:44 PM |
| FDA Lifts Clinical Hold on Bellicum's (BLCM) T Cell Therapy
www.msn.com - April 12 at 5:44 PM |
| Is Bellicum Pharmaceuticals Stock Now a Strong Buy?
finance.yahoo.com - April 12 at 5:44 PM |
 | After-Hours Movers 04/11: (QNST) (BLCM) (RETA) Higher; (BBBY) (NVAX) (COOL) Lower (more...)
www.streetinsider.com - April 12 at 8:24 AM |
| Bellicum FDA Hold Is Lifted, Time To Get Back To Business
seekingalpha.com - April 12 at 8:24 AM |
| Bellicum Pharmaceuticals (BLCM) Stock Rating Upgraded by Wells Fargo
www.americanbankingnews.com - April 11 at 9:31 PM |
| Bellicum Pharmaceuticals (BLCM) Given a $18.00 Price Target by Raymond James Financial Analysts
www.americanbankingnews.com - April 11 at 7:19 PM |
| Bellicum Pharmaceuticals (BLCM) Given a $18.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - April 11 at 6:13 PM |
| Bellicum Announces Clinical Hold Lifted on U.S. Studies of BPX-501
finance.yahoo.com - April 11 at 5:38 PM |
| Bellicum Pharmaceuticals (BLCM) Rating Reiterated by Jefferies Group
www.americanbankingnews.com - April 11 at 1:23 PM |
| ValuEngine Downgrades Bellicum Pharmaceuticals (BLCM) to Strong Sell
www.americanbankingnews.com - April 10 at 7:50 PM |
| DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc. And Reminds Investors With Losses In Excess of $50,000 To Contact The Firm
finance.yahoo.com - April 9 at 5:26 PM |
| FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors With Losses Exceeding $100K of Class Action Against Bellicum Pharmaceuticals, Inc. (BLCM) & Lead Plaintiff Deadline: April 9, 2018
finance.yahoo.com - April 9 at 5:26 PM |
| APRIL 9 DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc. And Reminds Investors With Losses In Excess of $50,000 To Contact The Firm
finance.yahoo.com - April 5 at 10:03 AM |
| FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM) To Contact The Firm
finance.yahoo.com - April 2 at 5:32 PM |
| Bellicum Pharmaceuticals (BLCM) Upgraded by ValuEngine to "Sell"
www.americanbankingnews.com - March 31 at 1:04 PM |
| Bellicum Pharmaceuticals (BLCM) Lifted to "Sell" at BidaskClub
www.americanbankingnews.com - March 30 at 6:14 PM |
| DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc.
finance.yahoo.com - March 29 at 5:34 PM |
| $80,000.00 in Sales Expected for Bellicum Pharmaceuticals Inc (BLCM) This Quarter
www.americanbankingnews.com - March 29 at 10:42 AM |
| Bellicum Pharmaceuticals (BLCM) Cut to "Strong Sell" at BidaskClub
www.americanbankingnews.com - March 28 at 7:04 PM |
| Bellicum Pharmaceuticals Inc (BLCM) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - March 28 at 8:08 AM |
| Analysts Expect Bellicum Pharmaceuticals Inc (BLCM) to Post -$0.71 Earnings Per Share
www.americanbankingnews.com - March 27 at 1:24 AM |
| Bellicum Pharmaceuticals (BLCM) Lowered to Market Perform at Wells Fargo
www.americanbankingnews.com - March 26 at 11:38 AM |
| Bellicum Pharmaceuticals (BLCM) Rating Reiterated by Cantor Fitzgerald
www.americanbankingnews.com - March 26 at 11:02 AM |
| Bellicum Pharmaceuticals (BLCM) Downgraded by ValuEngine
www.americanbankingnews.com - March 25 at 8:10 PM |
 | Better Buy: Bellicum Pharmaceuticals, Inc. vs. Alnylam The Motley Fool - Motley Fool
www.fool.com - March 23 at 8:14 AM |
 | BLCM NOTICE: Rosen Law Firm Announces Filing of Class Action ... - PR Newswire (press release)
www.prnewswire.com - March 22 at 8:19 AM |
| BLCM NOTICE: Rosen Law Firm Announces Filing of Class Action Against Bellicum Pharmaceuticals, Inc. - BLCM
finance.yahoo.com - March 21 at 5:42 PM |
| SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Bellicum Pharmaceuticals, Inc. (BLCM) & Lead Plaintiff Deadline: April 9, 2018
finance.yahoo.com - March 19 at 5:22 PM |
| Brokers Issue Forecasts for Bellicum Pharmaceuticals Inc's FY2018 Earnings (BLCM)
www.americanbankingnews.com - March 19 at 5:04 AM |
| Upcoming Conversation With An Expert: Understanding Bellicum's BPX-501 Potential In The Transplant Setting - Seeking Alpha
seekingalpha.com - March 18 at 8:12 AM |
| Bellicum Pharmaceuticals (BLCM) Given a $10.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - March 17 at 9:58 PM |
 | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bellicum ... - Business Wire (press release)
www.businesswire.com - March 17 at 8:19 AM |
| Bellicum Impresses In AML Study, Offers Hope - Seeking Alpha
seekingalpha.com - March 17 at 8:19 AM |
| BELLICUM LEAD PLAINTIFF ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding ... - PR Newswire (press release)
www.prnewswire.com - March 17 at 8:19 AM |
| Brokers Set Expectations for Bellicum Pharmaceuticals Inc's FY2018 Earnings (BLCM)
www.americanbankingnews.com - March 16 at 10:42 AM |
Bellicum Pharmaceuticals (NASDAQ:BLCM) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Bellicum Pharmaceuticals (NASDAQ:BLCM) Income Statement, Balance Sheet and Cash Flow Statement
Bellicum Pharmaceuticals (NASDAQ BLCM) Stock Chart for Saturday, April, 21, 2018
Loading chart…
